Kvantify hires Dr David Siebert to lead global business development

Kvantify has appointed Dr. David Siebert as SVP and Global Head of Business Development as part of a wider expansion of its commercial team.

He joins as the Danish quantum software company looks to widen adoption of its hybrid quantum-classical software in life sciences and related research markets. Rather than waiting for broader commercial maturity in quantum computing, Kvantify is targeting industrial users now.

Siebert brings experience across scientific and commercial roles in the TechBio and contract research organisation sectors. He has spent more than seven years in international scientific business development and will lead efforts to build partnerships and expand market reach.

Before joining the Copenhagen-based company, he worked at Syngene and previously held roles at Schrödinger and Avantor, where he helped expand strategic partnerships in global life sciences markets.

His academic background includes a PhD in medicinal chemistry from TU Wien and an MBA from Zürich International Business School. That combination of scientific training and commercial education reflects the profile many specialist software and drug discovery businesses seek as they try to turn complex research tools into repeatable commercial sales.

At Kvantify, the remit extends beyond a conventional sales role. There is not yet an established market for hybrid quantum-classical technology, so business development teams must identify use cases, educate customers and build relationships with early adopters even as the product category develops.

"There is no established market for hybrid quantum-classical technology - yet, and therefore we build the market while we build the technology. This requires a highly skilled business development team, which is why we are very excited that David is joining and leading our efforts", said Dr. Jörg Weiser, Executive Chairperson of Kvantify.

Siebert's arrival is not the only recent addition. Glenn Jordan has also joined as VP of business development, bringing more than 25 years of experience in technology, life sciences and healthcare.

Jordan's most recent roles included positions at Genomics and IQVIA. Together, the two hires suggest Kvantify is placing greater emphasis on commercial execution as it tries to convert interest in quantum-related research software into longer-term customer relationships.

Global reach

Kvantify is also extending its geographical coverage through external business partners. Although the company is headquartered in Denmark and sits within the country's quantum technology ecosystem, its target markets are international.

To support that expansion, Molecular Solutions Software, led by Dr. Raghu Rangaswamy, will cover markets from the Middle East to South East Asia from a base in India. TMK SOYAKU, led by Dr. Tomoko Satoh, will cover Japan.

The partner model points to a push into overseas markets without building a full direct presence in each territory. Both partner leaders are described as former senior executives at Schrödinger in India and Japan respectively, giving Kvantify access to established life sciences and computational chemistry networks.

Founded in 2022, the company develops software for quantum and classical computers, with a focus on early-stage drug discovery in the life sciences industry. It employs 49 people.

Kvantify argues that combining quantum and classical computing can improve molecular discovery and help researchers address industrial problems. That places it among a group of companies trying to demonstrate practical value from quantum-related techniques in chemistry and biology before large-scale quantum systems become widely available.

In this field, the commercial challenge is often as significant as the technical one. Prospective customers may be interested in the science but cautious about procurement, integration and return on investment, especially in a market that remains early-stage and comparatively untested.

That is why specialist business development hires matter. Companies need executives who can speak to both scientific teams and commercial decision-makers while navigating the long sales cycles common in drug discovery and research software.

"I am pleased to join Kvantify at such a pivotal moment for quantum-driven technologies and look forward to working with a talented team and visionary partners to help shape and drive transformative impact across the life sciences and beyond", said Siebert.

Professor Nikolaj Zinner, Co-founder and CSO, described the appointments as part of a broader effort to connect Kvantify's technology with research organisations working on difficult scientific problems.

"We are very happy to welcome David and Glenn to Kvantify. We are convinced that they will take our business development efforts to a whole new level, enabling our technology to solve complex problems in research organizations", said Zinner.